261 related articles for article (PubMed ID: 11531834)
21. Change of treatment from cyclosporin to mycophenolate mofetil in severe psoriasis.
Davison SC; Morris-Jones R; Powles AV; Fry L
Br J Dermatol; 2000 Aug; 143(2):405-7. PubMed ID: 10951153
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of LAS41008 (dimethyl fumarate) in adults with moderate-to-severe chronic plaque psoriasis: a randomized, double-blind, Fumaderm
Mrowietz U; Szepietowski JC; Loewe R; van de Kerkhof P; Lamarca R; Ocker WG; Tebbs VM; Pau-Charles I
Br J Dermatol; 2017 Mar; 176(3):615-623. PubMed ID: 27515097
[TBL] [Abstract][Full Text] [Related]
23. A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis.
Papp KA; Menter MA; Raman M; Disch D; Schlichting DE; Gaich C; Macias W; Zhang X; Janes JM
Br J Dermatol; 2016 Jun; 174(6):1266-76. PubMed ID: 26800231
[TBL] [Abstract][Full Text] [Related]
24. Double-blind placebo-controlled study of long-term low-dose cyclosporin in the treatment of palmoplantar pustulosis.
Erkko P; Granlund H; Remitz A; Rosen K; Mobacken H; Lindelöf B; Reitamo S
Br J Dermatol; 1998 Dec; 139(6):997-1004. PubMed ID: 9990362
[TBL] [Abstract][Full Text] [Related]
25. Cyclosporine in severe psoriasis. Results of a meta-analysis in 579 patients.
Faerber L; Braeutigam M; Weidinger G; Mrowietz U; Christophers E; Schulze HJ; Mahrle G; Meffert H; Drechsler S
Am J Clin Dermatol; 2001; 2(1):41-7. PubMed ID: 11702620
[TBL] [Abstract][Full Text] [Related]
26. Severe atopic dermatitis treated with everolimus.
Van Velsen SG; Haeck IM; Bruijnzeel-Koomen CA
J Dermatolog Treat; 2009; 20(6):365-7. PubMed ID: 19954394
[TBL] [Abstract][Full Text] [Related]
27. Mycophenolate mofetil as a systemic antipsoriatic agent: positive experience in 11 patients.
Geilen CC; Arnold M; Orfanos CE
Br J Dermatol; 2001 Mar; 144(3):583-6. PubMed ID: 11260019
[TBL] [Abstract][Full Text] [Related]
28. Increased bioavailability and improved efficacy, in severe psoriasis, of a new microemulsion formulation of cyclosporin.
Gulliver WP; Murphy GF; Hannaford VA; Primmett DR
Br J Dermatol; 1996 Sep; 135 Suppl 48():35-9. PubMed ID: 8881903
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of preprandial versus postprandial administration of low-dose cyclosporin microemulsion (Neoral) in patients with psoriasis vulgaris.
Hashizume H; Ito T; Yagi H; Takigawa M; Kageyama H; Furukawa F; Hata M; Shirahama S; Tanaka M; Higashishiba T; Machida H; Tsushima T; Matsushita K
J Dermatol; 2007 Jul; 34(7):430-4. PubMed ID: 17584318
[TBL] [Abstract][Full Text] [Related]
30. [The first experience with sirolimus (Rapamune) after kidney transplantation in Lithuania].
Asakiene E; Rainiene T; Dainys B
Medicina (Kaunas); 2005; 41 Suppl 1():93-100. PubMed ID: 15901984
[TBL] [Abstract][Full Text] [Related]
31. Intermittent short courses of cyclosporin (Neoral(R)) for psoriasis unresponsive to topical therapy: a 1-year multicentre, randomized study. The PISCES Study Group.
Ho VC; Griffiths CE; Albrecht G; Vanaclocha F; León-Dorantes G; Atakan N; Reitamo S; Ohannesson A; Mørk NJ; Clarke P; Pfister P; Paul C
Br J Dermatol; 1999 Aug; 141(2):283-91. PubMed ID: 10468801
[TBL] [Abstract][Full Text] [Related]
32. Severe psoriasis treated with a new macrolide: everolimus.
Frigerio E; Colombo MD; Franchi C; Altomare A; Garutti C; Altomare GF
Br J Dermatol; 2007 Feb; 156(2):372-4. PubMed ID: 17223881
[TBL] [Abstract][Full Text] [Related]
33. Weight loss improves the response of obese patients with moderate-to-severe chronic plaque psoriasis to low-dose cyclosporine therapy: a randomized, controlled, investigator-blinded clinical trial.
Gisondi P; Del Giglio M; Di Francesco V; Zamboni M; Girolomoni G
Am J Clin Nutr; 2008 Nov; 88(5):1242-7. PubMed ID: 18996858
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of systemic methotrexate in two fixed doses of 10 mg or 25 mg orally once weekly in adult patients with severe plaque-type psoriasis: a prospective, randomized, double-blind, dose-ranging study.
Dogra S; Krishna V; Kanwar AJ
Clin Exp Dermatol; 2012 Oct; 37(7):729-34. PubMed ID: 22830389
[TBL] [Abstract][Full Text] [Related]
35. Body-weight-independent dosing of cyclosporine micro-emulsion and three times weekly maintenance regimen in severe psoriasis. A randomised study.
Thaçi D; Bräutigam M; Kaufmann R; Weidinger G; Paul C; Christophers E
Dermatology; 2002; 205(4):383-8. PubMed ID: 12444336
[TBL] [Abstract][Full Text] [Related]
36. Psoriasis relapse evaluation with week-end cyclosporine A treatment: results of a randomized, double-blind, multicenter study.
Colombo D; Cassano N; Altomare G; Giannetti A; Vena GA
Int J Immunopathol Pharmacol; 2010; 23(4):1143-52. PubMed ID: 21244763
[TBL] [Abstract][Full Text] [Related]
37. A multicenter, randomized, open-label pilot trial assessing the efficacy and safety of etanercept 50 mg twice weekly followed by etanercept 25 mg twice weekly, the combination of etanercept 25 mg twice weekly and acitretin, and acitretin alone in patients with moderate to severe psoriasis.
Lee JH; Youn JI; Kim TY; Choi JH; Park CJ; Choe YB; Song HJ; Kim NI; Kim KJ; Lee JH; Yoo HJ
BMC Dermatol; 2016 Jul; 16(1):11. PubMed ID: 27455955
[TBL] [Abstract][Full Text] [Related]
38. Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized, controlled trial.
Papp KA; Bressinck R; Fretzin S; Goffe B; Kempers S; Gordon KB; Caro I; Walicke PA; Wang X; Menter A;
Int J Dermatol; 2006 May; 45(5):605-14. PubMed ID: 16700803
[TBL] [Abstract][Full Text] [Related]
39. Quality of life and clinical outcome in psoriasis patients using intermittent cyclosporin.
Touw CR; Hakkaart-Van Roijen L; Verboom P; Paul C; Rutten FF; Finlay AY
Br J Dermatol; 2001 May; 144(5):967-72. PubMed ID: 11359382
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of ISA247 in plaque psoriasis: a randomised, multicentre, double-blind, placebo-controlled phase III study.
Papp K; Bissonnette R; Rosoph L; Wasel N; Lynde CW; Searles G; Shear NH; Huizinga RB; Maksymowych WP
Lancet; 2008 Apr; 371(9621):1337-42. PubMed ID: 18424323
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
